Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
Rydex Biotechnology H RYOAX
- NAV / 1-Day Return 57.76 / −0.19 %
- Total Assets 100.9 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.640%
- Distribution Fee Level High
- Share Class Type No Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 61%
USD | NAV as of Apr 24, 2024 | 1-Day Return as of Apr 24, 2024, 10:22 PM GMT+0
Morningstar’s Analysis RYOAX
Will RYOAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 40.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 9.09 | 10.3 Mil | Healthcare |
Amgen Inc | 5.75 | 6.5 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 4.49 | 5.1 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.20 | 4.8 Mil | Healthcare |
Gilead Sciences Inc | 3.66 | 4.1 Mil | Healthcare |
Corteva Inc | 3.17 | 3.6 Mil | Basic Materials |
Moderna Inc | 2.87 | 3.2 Mil | Healthcare |
AstraZeneca PLC ADR | 2.56 | 2.9 Mil | Healthcare |
Biogen Inc | 2.53 | 2.9 Mil | Healthcare |
Illumina Inc | 2.41 | 2.7 Mil | Healthcare |